Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
Ares targets $2bn+ for new Asia special situations fund amid regional credit expansion
Ares targets $2bn+ for new Asia special situations fund amid regional credit expansion Ares...
Partners Group and Sella launch Italy’s first evergreen private equity ELTIF fund for retail investors
Partners Group and Sella launch Italy’s first evergreen private equity ELTIF fund for retail...
Blackstone, Apollo among PE heavyweights circling Forward Air in $2.5bn strategic review
Blackstone, Apollo among PE heavyweights circling Forward Air in $2.5bn strategic review...